Ocugen's Retinal Gene Therapy Pipeline Receives 'Buy' Rating from Canaccord Genuity, Highlighting Progress in IRDs

Illustration of the eye cross-section showing the retina at the back of the eye

Biotech Press Release · Published 2026-08-06 · Read the original article source

Promising Developments for Inherited Retinal Disease Community

News from the biotech sector indicates potential advancements for individuals and families affected by inherited retinal diseases (IRDs). Canaccord Genuity, a financial advisory firm, has initiated coverage on Ocugen (OCGN:NASDAQ) with a